SSTR-expressing Tumors

1

Review clinical trials related to SSTR-expressing Tumors. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies

Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin receptors (SSTR) which requires specific PET scan tracers to sufficiently capture on images. The current standard of care tracer at BC Cancer for SSTRs on NETs is 68Ga-DOTATATE. This project seeks to identify if 18F-AmBF3-TATE (a tracer that has established safety from phase 1 trial results), is comparable in disease detection, no. of lesions identified, image quality, safety and overall accuracy, to 68Ga-DOTATATE.

Participants needed: 51
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: British Columbia Cancer AgencyUpdated: Jun 2, 2026Locations: 1
Eligibility criteria

Age ≥18 years [+1]

Pregnant and breast-feeding patients. [+2]